Lexicon Pharmaceuticals | LXRX - Ebitda


Lexicon Pharmaceuticals reported $-12.04M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 3.27B 178M Dec/2025
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Illumina USD 469M 137M Dec/2025
Insmed USD -148.3M 165.88M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 7.19B 2.32B Dec/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD -3.05M 20.97M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Novartis USD 5.3B 530M Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Thermo Fisher Scientific USD 2.7B 464M Mar/2026
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024